Ben Withey
Director, Commercial Diagnostics, CDx Lead Pfizer
Seminars
Wednesday 7th October 2026
Panel Discussion: Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology
2:10 pm
- Tumor heterogeneity determines treatment response and resistance, and AI-powered computational pathology makes heterogeneity tractable for drug development
- Tissue analysis succeeds in drug development when scientific, computational, and delivery expertise are integrated from the start, not assembled project by project
- Connecting imaging features to outcomes to generate predictive biomarkers, and translation into cross-cohort and cross-platform validation and deployment
- Infrastructure and global access shape which biomarkers can actually reach patients. H&E-based approaches can have an important role in ensuring equitable, global CDx access
